



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

636.MYELODYSPLASTIC SYNDROMES-BASIC AND TRANSLATIONAL

Outcome Prediction in *DDX41*-Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Carmelo Gurnari, MD^{1,2}, Hideki Makishima, MDPhD³, Arda Durmaz¹, Ryunosuke Saiki³, Guilherme Mendes Sapinho^{4,5}, Alex Bataller, MDPhD⁶, Lukasz P. Gondek, MDPhD⁷, Yasuhito Nannya³, Steve Best⁴, Pramila Krishnamurthy⁴, Hussein Awada¹, Enrico Attardi, MD⁸, Valeria Visconte, PhD¹, Maria Teresa Voso, MD⁸, Amy E. DeZern, MDMHS⁹, Guillermo Garcia-Manero, MD⁶, Austin Kulasekararaj, MD PhD MPH¹⁰, Jaroslaw P. Maciejewski, MD, PhD, FACP¹, Seishi Ogawa, MD PhD¹¹

¹ Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

² Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

³ Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁴ Department of Haematological Medicine, King's College Hospital NHS, London, United Kingdom

⁵ Serviço de Hematologia e Transplantação de Medula, Centro Hospitalar Lisboa Norte, Lisbon, Portugal

⁶ The University of Texas MD Anderson Cancer Center, Houston, TX

⁷ Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD

⁸ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

⁹ Johns Hopkins University, Baltimore, MD

¹⁰ Department of Haematological Medicine, King's College Hospital, London, United Kingdom

¹¹ Department of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Hypomorphic *DDX41* mutations are prototypic lesions for germline predisposition to late onset myeloid neoplasia (MN), chiefly MDS. In a recent study¹, we demonstrated that germline mutations in this gene are found in up to 5% of MDS cases and explain nearly 80% of the etiologic fraction of known MN inherited predisposition. *DDX41* mutation carriers have a ~50% lifetime risk of developing MN, which commonly accompanies the acquisition of a secondary somatic *DDX41* mutation in the contralateral allele (most commonly p.R525H) with a strong male predominance. Because of these peculiarities, risk classification assigned by currently available schemes such as the revised/molecular international prognostic scoring system (IPSS-R/M) has also been questioned, differentiating *DDX41*-mutant MDS as a distinct nosologic subentity, whereby current prognostic tools are not able to capture invariant biologic features crucial for outcome prediction. Particularly, the impact of somatic *DDX41* mutations on disease progression has not been evaluated.

In this study, we explored the applicability of current schemes used for MDS outcome prediction leveraging an international collaboration across 6 academic centers. We accrued a total of 238 MDS cases from a cohort of 409 MN patients with *DDX41* mutations with clinical-molecular annotations and relevant follow up data. For relevant comparisons, a cohort of 1212 *DDX41* wild-type (WT) MDS cases with matching annotations and follow up was used.

Overall, the median age at MDS diagnosis was 69 years (IQR 61-76) with a strong male predominance (4.4 M:F ratio). According to IPSS-R, patients clustered in very low (10%), low (17%), intermediate (34%), high (20%) and very high (18%) risk groups, whereas by IPSS-M the redistribution of risk categories was as follows: very low (7%), low (27%), moderate low (18%), moderate high (16%), high (15%), and very high (17%). After merging the moderate low/high IPSS-M categories for comparison purposes, the overall shift was 51%, with 38% up- and 62% down-staged. Notably, pairwise Log-Rank tests across IPSS-R/M risk categories resulted in non-significant survival differences in majority of subgroups, pinpointing how these commonly used schemes fail in separating *DDX41*-mutant MDS into groups of diverse prognoses. Conversely, the same analysis in the WT cohort led to a significant separation and identification of distinct prognostic categories. (**Fig1A**)

Next, we examined the reasons why *DDX41*-mutant MDS cases defy accuracy of current prognostic schemes. When looking at *DDX41* specific genomic configuration, cases with germline plus p.R525H somatic mutations showed higher bone marrow blast percentages (median 11%) vs those acquiring other secondary somatic hits (4%, $p < .001$) or harboring only 1 germline alteration (7%, $p = .002$). By dividing patients according to IPSS-R scores (lower < 3.5 , higher-risk > 3.5), we noticed a twice

higher frequency of adverse risk MDS among patients with germline plus p.R525H mutations ($p=.009$). Thus, we explored whether *DDX41* specific mutational configuration may have a role in driving MDS outcomes. While no survival difference was found between cases with germline alone vs germline plus somatic configuration, the dissection of the genomic architecture of double mutants showed worse survival outcomes and faster leukemia evolution in cases carrying truncating and/or p.R525H mutations (**Fig1B**). These features still held significance in a *DDX41*-specific multivariable model for leukemia progression considering age and gender, with the best goodness of fit (Akaike Information Criterion-AIC: 131; c-index: 0.81) as compared to IPSS-R (AIC: 150, c-index: 0.71) and IPSS-M (AIC: 144, c-index: 0.73), whereas the acquisition of p.R525H mutation was the only independent predictor of survival (HR=3.9, 95% CI 1.5-9.9, $p=.005$).

We show that IPSS-R/M are not able to adequately assess leukemic evolution and survival outcomes in *DDX41*-mutant MDS. Indeed, germline truncating and somatic p.R525H mutations are better predictors of faster leukemic evolution and survival. Additional risk factors inherent to this MDS subentity hold a prognostic significance beyond the consideration of traditional disease-specific variables, substantiating the need for a dedicated risk scoring system. This refined prognostication approach is also a consideration for other known germline mutations with predisposition to MN.

Disclosures Mendes Sapinho: Abbvie: Honoraria. **Voso:** Jazz: Other: Advisory Board; Syros: Other: Advisory Board; Abbvie: Speakers Bureau; Jazz: Speakers Bureau; Celgene/BMS: Research Funding, Speakers Bureau; Novartis: Research Funding; Astellas: Speakers Bureau; Celgene/BMS: Other: Advisory Board; Novartis: Speakers Bureau; Astra Zeneca: Speakers Bureau. **DeZern:** Bristol Myers Squibb: Consultancy; Caribou: Membership on an entity's Board of Directors or advisory committees; Geron: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy; Appellis: Consultancy, Membership on an entity's Board of Directors or advisory committees. **Garcia-Manero:** Bristol Myers Squibb: Other: Medical writing support, Research Funding; Genentech: Research Funding; AbbVie: Research Funding. **Kulasekararaj:** F. Hoffmann-La Roche Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees; Akari Therapeutics: Consultancy; Celgene/BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BioCryst: Consultancy; Samsung: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion, AstraZeneca Rare Disease: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Achillion: Consultancy. **Maciejewski:** Omeros: Consultancy; Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; Regeneron: Consultancy, Honoraria.

<https://doi.org/10.1182/blood-2023-178116>




Figure 1